EDITORIAL

COVID-19: not a contraindication for surgery in patients with proximal femur fragility fractures

Ilaria Morelli¹, Francesco Luceri², Riccardo Giorgino¹, Riccardo Accetta³, Paolo Perazzo⁴, Laura Mangiavini^{5,2}, Nicola Maffulli^{6,7,8*} and Giuseppe M. Peretti^{5,2}

Keywords: COVID-19, Proximal femur fractures, Prognosis, Surgical treatment, Fragility fractures

During the SARS-CoV-2 outbreak, Italy was the leading country for the number of new positive cases from March 8 2020, to March 21, and the first for the total number of deaths from March 19, to April 12 2020 [1– 4]. The Italian National Healthcare System required the conversion of many wards into COVID-19 care units, and the suspension of deferrable treatments, surgical procedures and outpatient visits, to dedicate human and material resources to free Intensive Care Unit (ICU) beds. In the most struck regions, some hospitals were designated as hubs for non-delayable treatments [5, 6]. Our institution (IRCCS Orthopaedic Institute Galeazzi) was chosen amongst the Trauma Hubs.

Orthopaedic trauma surgery focused mainly on femoral fragility fractures in the elderly, since the "lockdown" began on March 10, 2020. Proximal femur fractures carry a high mortality rate [7], and the standard of care involves surgery within 48 h from the trauma [8]. These elderly patients are also the most susceptible to the nefarious consequences of COVID-19 [9]. Thus, orthopaedic surgeons face the daily dilemma of performing life-saving surgery on patients who, given their severe respiratory compromise, have a higher risk of peri-operative death. Preliminary reports from Wuhan, Bergamo (the Italian province with

BMC

conclusions on the possible benefit effects of surgery on COVID-19 patients with proximal femur fractures [10-12]. In the first case series, six patients reported proximal femur fractures, but only three were considered eligible for surgery because of no signs of pneumonia at CT scan or non-severe respiratory symptoms [10]. Three of them died, two after conservative management. Of the three surviving patients, two underwent surgery: the authors concluded that patients with proximal femoral fractures and COVID-19 have a higher risk of death. In a series of 16 such patients in Bergamo (Lombardy), Italy [11], three patients died before surgeries for respiratory failure. The other 13 patients (temperature < 38 °C, pO_2 > 90% and no signs of multiorgan dysfunction) underwent surgery, with four dying in the first postoperative week. Oxygen saturation improved after surgery in the survivors. Finally, a multicentre observational study on 136 proximal femoral fractures reported an overall 30.4% mortality in COVID-19 patients. The mortality rate was 67% in COVID-19 patients treated non-operatively, and only 4% in patients who underwent surgery [12].

The early outcomes (March 17–April 17, 2020) from our Trauma hub endorse the "to fix" faction. Ten swabconfirmed COVID-19 patients (8 women and 2 men) with a mean age of 83.9 ± 7.4 years (range 72-98) underwent surgical treatment for their proximal femoral fractures within 48 h from admission at our facility: 8 patients received intramedullary nailing for AO 31A fractures, and 2 received hemiarthroplasty for AO 31B fractures [13]. The

© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, wish http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.





updates

Open Access

^{*} Correspondence: n.maffulli@qmul.ac.uk

⁶Department of Medicine, Surgery and Dentistry, University of Salerno, Via S. Allende, 84081 Baronissi, (SA), Italy

⁷Barts and the London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, Mile End Hospital, Queen Mary University of London,

²⁷⁵ Bancroft Road, London E1 4DG, UK

Full list of author information is available at the end of the article

	Case n°	-	2	3	4	5	9	7	8	6	10
	Sex	ш	ш	W	ш	ш	ш	Ŀ	F	ц	Σ
	Age	85	72	85	89	77	98	81	81	80	91
	Hospital stay (days)	22	00	13	6	6	6	12	12	29	7
	Clinical history	AF, PD, NIDD M			HTN, HT	HTN, PD, HCL, MPD	Coronary artery disease	Coronary artery disease	NTH	HTN, PD	
	Fracture	Left, AO31A	Left, A031A	Left, AO31A	Right, AO31A	Right, AO31A	Right, AO31A	Right, AO31A	Left, AO31A	Right, AO31B	Right,
	SARS-CoV-2 quantitative RT-PCR	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive
	Surgery	PFN	PFN	PFN	PFN	PFN	PFN	PFN	PFN	НА	ЧA
	Postoperative blood transfusions (N)	0	0	0	0	2	, -	0	2	2	
	Complications		I	UTI, Pericardial effusion	Respiratory failure		Respiratory failure	ı		III	Respirat failure
	Chest X-ray	Positive	Positive	Negative	Positive	Positive	Negative	Positive	Negative	Positive	Negativ
	Mechanical ventilation	No	No	No	No	No	No	No	No	No	No
Oxygen support through Venturi	Admission	No (SaO2 94% in AA)	No (SaO2 96% in AA)	No (SaO2 95% in AA)	No (SaO2 93% in AA)	4 L/min (SaO2 94%)	No (SaO2 90% in AA)	No (SaO2 97% in AA)	No (SaO2 96% in AA)	No (SaO2 93% in AA)	No (Sa 96% in
mask (L/min)	First 3 days of hospitalization	6 L/min	8 L/min	6 L/min	No	4 L/min	2 L/min	2 L/min	2 L/min	4 L/min	8 L/mir
	Major level needed during hospitalization	10 L/min	8 L/min	6 L/min	No	6 L/min	4	5	2	œ	Ø
	Discharge	No (SaO2 96% in AA)	No (SaO2 96% in AA)	No (SaO2 96% in AA)	ı	No (SaO2 96% in AA)	ı	2 L/min (SaO2 96%)	No (SaO2 96% in AA)	No (SaO2 93% in AA)	No (Sa(96% in
	Discharge mode	COVID-19 Rehabilitation Unit	COVID-19 Rehabilitation Unit	COVID-19 Rehabilitation Unit	Death	COVID-19 Rehabilitation Unit	Death	COVID-19 Rehabilitation Unit	COVID-19 Rehabilitation Unit	COVID-19 Rehabilitation Unit	COVID- Rehabil Unit
	Follow-up (days)	31	29	23	18	18	15	14	16	39	35

Table 2 Comparison of patients' mear	n laboratory parameters a	at admission and postoperat	ive days 1 and 5 \pm 2		
Laboratory parameters	Mean value ± SD at D0	Mean value ± SD at POD 1	Mean value ± SD at POD 5 ± 2	Post hoc test (p value)	F statistic (ANOVA)
Leucocyte count (\times 10 ³ /mL)	10.42 ± 3.4	10.46 ± 2.8	8.65 ± 3.1	D0 vs POD1: $p = 1$ POD1 vs 5 ± 2: $p = 0.045$	$F_{(1.585, 14.261)} = 5.644, p = 0.02$
Absolute neutrophil count (\times 10 ³ /mL)	8.46 ± 2.9	8.46 ± 2.4	6.49 ± 2.6	D0 vs POD1: $p = 1$ POD1 vs 5 ± 2: $p = 0.026$	$F_{(1.849, 16.645)} = 6.733, p = 0.008$
Relative lymphocyte count (%)	11.4 ± 3.2	11.2 ± 5.9	16.3 土 6.1	D0 vs POD1: $p = 1$ POD1 vs 5 ± 2: $p = 0.02$	$F_{(1.602, 14.420)} = 5.611, p = 0.02$
Univariate repeated measures ANOVA with Gre	senhouse-Geisser correction an	d post hoc tests using the Bonferr	oni adjustment (statistical significance	set at $p \leq 0.05$)	

(Statistic ILIE adjus using the Bonterroni Univariate repeated measures ANOVA with Greenhouse-Geisser correction and post hoc tests of F statistic reported as F(degrees of freedom_{time}, degrees of freedom_{erro}) = F value, p value) Only significant outcomes are reported in this table Abbreviations: D0 admission day, SD standard deviation, POD postoperative day

mean oxygen saturation on admission was 94.4% (range 90-97), breathing ambient air by 9 patients and 4 litres/ minute oxygen through Venturi mask by 1 patient. In 6 patients, atypical pneumonia was evident on plain chest radiographs on admission. Three patients underwent a further plain chest radiograph after surgery (one showed improvement, one a stable pulmonary involvement and in one patient the pneumonia worsened). Four patients developed systemic complications, including respiratory failure as reported in Table 1. Only two of these patients died, both 8 days after surgery: one of them had pneumonia on plain chest radiographs on admission. Both these patients presented the lowest oxygen saturation breathing ambient air on admission (93% and 90%, respectively). The mean length of stay in the Trauma Unit was 12.9 \pm 6.9 days (range 7-29), and the surviving patients were finally discharged to our in-hospital rehabilitation unit with an improved or stable oxygen saturation, with 7 of the 8 surviving patients needing no further oxygen support.

Our patients exhibited the lowest death rate (20%) to date, but, given the heterogeneous data reported by the other two case series, and the missing individual patient data of the multicentric study, the reasons for this favourable finding are unclear. In our centre, surgery for proximal femur fractures in the elderly is performed within 48 h from admission in more than 95% of patients, and this was the case for all COVID-19 patients. Two of the three operated patients reported by Mi et al. received surgery 5, 2 and 3 days after admission [10]. Catellani et al. reported surgery within 24 h after admission for 10 patients, whilst in three cases, it was postponed for haemorrhagic risk as the patients were using anticoagulant drugs [11]. Muñoz-Vives reported a mean delay from admission to surgery of 2.4 days (range 0-13) [12]. Secondly, an internal protocol, based on the previously published evidence of microvascular pulmonary thrombosis in patients with COVID-19, established the administration of low molecular weight heparin, doubling the prophylactic dose (enoxaparin sodium 4000 U.I. twice daily), as the nasopharyngeal swab showed positivity for SARS-CoV-2 [14]. The thromboembolic prophylactic therapy, if administered, was not reported by Mi and Muñoz-Vives, whilst Catellani et al. do not specify the dosage they used [10-12]. Finally, the presence of different SARS-CoV-2 clusters may explain the differences with the Chinese and Spanish studies, but it is unlikely that the viral type differed between Milan and Bergamo, two cities 60 km apart [15].

Furthermore, we retrospectively analysed the evolution of their laboratory parameters at admission, 1st and 5th \pm 2 postoperative days (POD1 and POD 5 \pm 2) performing a univariate repeated measures ANOVA with Greenhouse-Geisser correction and post hoc tests using the Bonferroni adjustment (statistical significance set at $p \le 0.05$; *F* statistic reported as *F*(degrees of freedom_{time}, degrees of freedom_{error}) = *F* value, *p* value). Single-patients laboratory parameters are available online as Additional file 1. Our patients demonstrated a significant reduction in leukocyte and neutrophils count and an increase in lymphocyte relative count (Table 2) comparing POD1 and POD 5 ± 2, possibly explained by the time from surgery and by the COVID-19 infection resolution, with an improvement of the peculiar SARS-CoV-2-related lymphopenia [16]. This is a noteworthy finding, considering that a low lymphocyte percentage has been considered a negative prognostic factor for COVID-19 [17].

The beneficial effects of early standard surgical care for proximal femoral fractures in the elderly seem to be confirmed also in COVID-19 patients. In-hospital management of fracture-related and cytokine-induced musculoskeletal pain in COVID-19 patients should take into account the recent warnings about the use of common NSAIDs in case of SARS-CoV-2 infection [18–20]. Nevertheless, the mortality after proximal femur fractures remains high, especially during the first year after the fracture, and COVID-19 needs a very long time for viral clearance [21, 22]. The contribution of surgery to improve respiratory and laboratory values in COVID-19 patients with femur fractures should be verified by further studies with a longer follow-up and with control groups.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10. 1186/s13018-020-01800-9.

Additional file 1. Laboratory values during hospitalization.

Acknowledgements

None

Authors' contributions

All individuals listed as authors meet the criteria for authorship according to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, with the following contributions: study concept and design (IM, RA, PP, LM, NM, GMP), data acquisition (IM, FL, RG), analysis and interpretation of data (IM, NM, GMP), first draft writing (IM), critical revision of the manuscript (FL, RG, RA, PP, LM, NM, GMP). Prior to its submission, all authors have reviewed and confirmed the accuracy of the whole manuscript.

Funding

None

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.

Ethics approval and consent to participate

This study was performed according to the Declaration of Helsinki. Institutional Approval for the publication of this article was obtained. Institutional consent to retrospectively use patients' data for research was obtained.

Consent for publication

All patients' identifying data have been omitted. Institutional consent to retrospectively use patients' data for research was obtained.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Residency Program in Orthopaedic and Traumatology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy. ²Equipe of Regenerative and Reconstructive Orthopaedics (EUORR) Unit, IRCCS Istituto Ortopedico Galeazzi, Via Riccardo Galeazzi 4, 20161 Milano, Italy. ³Trauma Unit and Emergency Department, IRCCS Istituto Ortopedico Galeazzi, Via Riccardo Galeazzi 4, 20161 Milano, Italy. ⁴Anesthesiology Service and Intensive Care Unit, IRCCS Istituto Ortopedico Galeazzi 4, 20161 Milano, Italy. ⁵Department of Biomedical Sciences for Health, University of Milan, Via Mangiagalli 31, 20133 Milan, Italy. ⁶Department of Medicine, Surgery and Dentistry, University of Salerno, Via S. Allende, 84081 Baronissi, (SA), Italy. ⁷Barts and the London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, Mile End Hospital, Queen Mary University of London, 275 Bancroft Road, London E1 4DG, UK. ⁸School of Pharmacy and Bioengineering, Keele University School of Medicine, Thornburrow Drive, Stoke on Trent ST4 7QB, UK.

Received: 4 July 2020 Accepted: 14 July 2020 Published online: 28 July 2020

References

- World Health Organization: Coronavirus disease 2019 (COVID-19). Situation Report – 83. 12/4/2020. https://www.who.int/docs/default-source/ coronaviruse/situation-reports/20200412-sitrep-83-covid-19.pdf?sfvrsn= 697ce98d_4. Accessed: 26/04/2020.
- World Health Organization: Coronavirus disease 2019 (COVID-19). Situation Report – 60. 19/3/2020. https://www.who.int/docs/default-source/ coronaviruse/situation-reports/20200320-sitrep-60-covid-19.pdf?sfvrsn=d2 bb4f1f_2. Accessed: 26/4/2020.
- World Health Organization: Coronavirus disease 2019 (COVID-19). Situation Report – 48. 8/3/2020. https://www.who.int/docs/default-source/ coronaviruse/situation-reports/20200308-sitrep-48-covid-19.pdf?sfvrsn=16 f7ccef_4. Accessed: 26/4/2020.
- World Health Organization: Coronavirus disease 2019 (COVID-19). Situation Report – 62. 21/3/2020. https://www.who.int/docs/default-source/ coronaviruse/situation-reports/20200322-sitrep-62-covid-19.pdf?sfvrsn=755 c76cd_2. Accessed: 26/4/2020.
- Chisci E, Masciello F, Michelagnoli S. Creation of a vascular surgical hub responding to the COVID-19 emergency: the italian USL Toscana Centro model. J Vasc Surg. 2020. https://doi.org/10.1016/j.jvs.2020.04.019.
- Giorgi PD, Villa F, Gallazzi E, Debernardi A, Schiro GR, Crisa FM, Talamonti G, D'Aliberti G. The management of emergency spinal surgery during the COVID-19 pandemic in Italy. Bone Joint J. 2020. https://doi.org/10.1302/ 0301-620X.102B6.BJJ-2020-0537.
- Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152:380–90. https:// doi.org/10.7326/0003-4819-152-6-201003160-00008.
- Hip Attack Investigators. Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial. Lancet. 2020;395:698–708. https://doi.org/10.1016/S0140-6736(20)30058-1.
- Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020. https:// doi.org/10.1016/j.jinf.2020.03.005.
- Mi B, Chen L, Xiong Y, Xue H, Zhou W, Liu G. Characteristics and early prognosis of COVID-19 infection in fracture patients. J Bone Joint Surg Am. 2020. https://doi.org/10.2106/JBJS.20.00390.
- Catellani F, Coscione A, D'Ambrosi R, Usai L, Roscitano C, Fiorentino G. Treatment of proximal femoral fragility fractures in patients with COVID-19 during the SARS-CoV-2 outbreak in Northern Italy. J Bone Joint Surg Am. 2020. https://doi.org/10.2106/JBJS.20.00617.
- Munöz-Vives JM, Jornet-Gibert M, Càmara-Cabrera J, Esteban PL, Brunet L, Delgado-Flores L, Camacho-Carrasco P, Torner P, Marcano-Fernandez F. Spanish HIP-COVID Investigation Group: Mortality rates of patients with

proximal femoral fracture in a worldwide pandemic. J Bone Joint Surg Am. 2020. https://doi.org/10.2106/JBJS.20.00686.

- Meinberg EG, Agel J, Roberts CS, Karam MD, Kellam JF. Fracture and dislocation classification compendium-2018. J Orthop Trauma. 2018; 32(Suppl 1):S1–S170. https://doi.org/10.1097/BOT.000000000001063.
- Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, Peccatori J, D'Angelo A, De Cobelli F, Rovere-Querini P, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020.
- Sheikh JA, Singh J, Singh H, Jamal S, Khubaib M, Kohli S, Dobrindt U, Rahman SA, Ehtesham NZ, Hasnain SE. Emerging genetic diversity among clinical isolates of SARS-CoV-2: lessons for today. Infect Genet Evol. 2020; 104330. https://doi.org/10.1016/j.meegid.2020.104330.
- Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, Damoraki G, Gkavogianni T, Adami ME, Katsaounou P, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020. https://doi.org/10.1016/j.chom. 2020.04.009.
- Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5:33. https://doi.org/10. 1038/s41392-020-0148-4.
- Ragni E, Mangiavini L, Viganò M, Brini AT, Peretti GM, Banfi G, De Girolamo L. Management of osteoarthritis during COVID-19 pandemic. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1910.
- De Girolamo L, Peretti GM, Maffulli N, Brini AT. Covid-19-The real role of NSAIDs in Italy. J Orthop Surg Res. 2020;15:165. https://doi.org/10.1186/ s13018-020-01682-x.
- Cipollaro L, Giordano L, Padulo J, Oliva F, Maffulli N. Musculoskeletal symptoms in SARS-CoV-2 (COVID-19) patients. J Orthop Surg Res. 2020;15: 178. https://doi.org/10.1186/s13018-020-01702-w.
- Gundel O, Thygesen LC, Gogenur I, Ekeloef S. Postoperative mortality after a hip fracture over a 15-year period in Denmark: a national register study. Acta Orthop. 2020;91:58–62. https://doi.org/10.1080/17453674.2019.1680485.
- Yang JR, Deng DT, Wu N, Yang B, Li HJ, Pan XB. Persistent viral RNA positivity during recovery period of a patient with SARS-CoV-2 infection. J Med Virol. 2020. https://doi.org/10.1002/jmv.25940.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

